Mount Sinai Medical Center

Name: Adil Hussain | DOB: 10/7/1981 | MRN: 3622990 | PCP: Provider Not In System | Legal Name: Adil Hussain

CARDIO IQ ADVANCED LIPID PANEL AND INFLAMMATION PANEL (QUEST)

Collected on Feb 04, 2025 12:16 PM

Results

FASTING:YES
MULTIPLE TESTING PRIORITIES; ROUTINE TESTING TO FOLLOW.

FASTING: YES

Cholesterol
Normal value: <200 mg/dL

Value
222

High

HDL
Normal value: >39 mg/dL

Value
48

Triglycerides
Normal value: <150 mg/dL

Value
109

LDL Calculated
Normal value: <100 mg/dL (calc)

Value
151

High

Desirable range <100 mg/dL for primary prevention; <70 mg/dL for patients with CHD or diabetic patients with >= 2 CHD risk factors.
LDL-C is now calculated using the Martin-Hopkins calculation, which is a validated novel method providing better accuracy than the Friedewald equation in the estimation of LDL-C. Martin SS et al. JAMA. 2013;310(19): 2061-2068 (http://education.QuestDiagnostics.com/faq/FAQ164)
LDL-C is now calculated using the Martin-Hopkins calculation, which is a validated novel method providing better accuracy than the Friedewald equation in the estimation of LDL-C.
Martin SS et al. JAMA. 2013;310(19): 2061-2068 (http://education.QuestDiagnostics.com/faq/FAQ164)

Chol/HDL Ratio
Normal value: <5.0 calc

Value
4.6

NON-HDL CHOLESTEROL
Normal value: <130 mg/dL (calc)

Value
174

High

For patients with diabetes plus 1 major ASCVD risk factor, treating to a non-HDL-C goal of <100 mg/dL (LDL-C of <70 mg/dL) is considered a therapeutic option.
For patients with diabetes plus 1 major ASCVD risk factor, treating to a non-HDL-C goal of <100 mg/dL (LDL-C of <70 mg/dL) is considered a therapeutic option.

LDL PARTICLES, TOTAL
Normal value: <1,138 nmol/L

Value
2,144

High

Relative Risk: Optimal <1138; Moderate 1138-1409; High >1409. Male and Female Reference Range: 1016 to 2185 nmol/L.

LDL, SMALL
Normal value: <142 nmol/L

Value
333

High

Relative Risk: Optimal <142; Moderate 142-219; High >219. Male Reference Range: 123 to 441 nmol/L; Female Reference Range: 115 to 386 nmol/L.

LDL, MEDIUM
Normal value: <215 nmol/L

Value
419

High

Relative Risk: Optimal <215; Moderate 215-301; High >301. Male Reference Range: 167 to 485 nmol/L; Female Reference Range: 121 to 397 nmol/L.

HDL, LARGE
Normal value: >6,729 nmol/L

Value
4,764

Low

Relative Risk: Optimal >6729; Moderate 6729-5353; High <5353. Male Reference Range: 4334 to 10815 nmol/L; Female Reference Range: 5038 to 17886 nmol/L.

LDL PATTERN

Normal value: A Pattern

Value

A

Relative Risk: Optimal Pattern A; High Pattern B. Reference Range: Pattern A.

LDL PARTICLE SIZE

Normal value: >222.9 Angstrom

Value

224.2

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Cardiometabolic Center of Excellence at Cleveland HeartLab. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes. Relative Risk: Optimal >222.9; Moderate 222.9-217.4; High <217.4. Male and Female Reference Range: 216 to 234.3 Angstrom. Adult cardiovascular event risk category cut points (optimal, moderate, high) are based on an adult U.S. reference population plus two large cohort study populations. Association between lipoprotein subfractions and cardiovascular events is based on Musunuru et al. ATVB.2009;29:1975. For additional information, please refer to http://education.QuestDiagnostics.com/faq/FAQ134 (This link is being provided for informational/educational purposes only.)

Apolipoprotein B

Normal value: <90 mg/dL

Value

130

High

Risk: Optimal <90 mg/dL; Moderate 90-119 mg/dL; High >= 120 mg/dL; Cardiovascular event risk category cut points (optimal, moderate, high) are based on National Lipid Association recommendations- Jacobson TA et al. J of Clin Lipid. 2015; 9: 129-169 and Jellinger PS et al. Endocr Pract. 2017;23(Suppl 2):1-87.

LIPOPROTEIN (a)

Normal value: <75 nmol/L

Value

19

Risk: Optimal <75 nmol/L; Moderate 75-125 nmol/L; High >125 nmol/L. Cardiovascular event risk category cut points (optimal, moderate, high) are based on Tsimika S. JACC 2017;69:692-711.

CARDIO CRP(R)

Normal value: <1.0 mg/L

Value

0.8

Reference Range: Optimal <1.0 mg/L, according to Jellinger PS et al. Endocr Pract.2017;23(Suppl 2):1-87. The AHA/CDC Guidelines recommend hs-CRP ranges for identifying Relative Cardiovascular Risk in patients ages >17 years: <1.0 mg/L Lower Relative Cardiovascular Risk; 1.0-3.0 mg/L Average Relative Cardiovascular Risk; 3.1-10.0 mg/L Higher Relative Cardiovascular Risk. If result is between 3.1 and 10.0 mg/L, consider retesting in 1-2 weeks to exclude a benign transient elevation secondary to infection or inflammation from the baseline CRP value. Persistent elevations of >10.0 mg/L upon retesting may be associated with infection and inflammation. The AHA/CDC recommendations are based on Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulatio
n 2003; 107(3): 499-511.
For ages >17 Years:
hs-CRP mg/L Risk According to AHA/CDC Guidelines
<1.0 Lower relative cardiovascular risk.
1.0-3.0 Average relative cardiovascular risk.
3.1-10.0 Higher relative cardiovascular risk.
Consider retesting in 1 to 2 weeks to exclude a benign transient elevation in the baseline CRP value secondary to infection or inflammation.
>10.0 Persistent elevation, upon retesting, may be associated with infection and inflammation.

Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107(3): 499-511.

LA PLA2 ACTIVITY
Normal value: <124 nmol/min/mL

Value
93

Relative Risk: Optimal <=123 nmol/min/mL; High >123 nmol/min/mL.
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
See Note 1

Note 1

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

Authorizing provider: Misra,Deepika
Collection date: Feb 04, 2025 12:16 PM
Specimens: Serum
Result date: Feb 10, 2025 3:40 PM
Result status: Final
Resulting lab:
QUEST